-
Christina Jewett
Posts
CPAP Lawsuits Settled for $1.1 Billion
Thousands of people with sleep apnea and other illnesses had sued the company, claiming flawed devices were harming them.
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is…
National Academy Asks Court to Strip Sackler Name From Endowment
Millions in Sackler donations sat dormant, rising in value as the opioid epidemic raged and as other institutions distanced themselves from the makers of a…
FDA Issues Alert on Heart Pump Linked to Deaths
The agency faulted the device maker for delayed notice of mounting complications, citing increasing reports of how use of the device perforated the walls of…
FDA Urges Recall of Lead-Tainted Cinnamon Brands
The agency tested 75 types of cinnamon after hundreds of children were poisoned by the spice in applesauce. It found some lead in cinnamon brands…
Top US Senators Urge Stores to Stop Sellng Illicit Vapes
Lawmakers want shopkeepers to remove e-cigarettes that were not authorized by the F.D.A. Retailers say it is not that simple.
Menthol Cigarette Bans Can Reduce Smoking Rates, Study Finds
As public health groups pressure the Biden administration to impose a ban on menthol cigarettes, research suggests similar moves in other countries have led to…
US Agencies Start Inquiry Into Generic Drug Shortages
The F.T.C. and H.H.S. are examining the tactics of group purchasing organizations that generic industry executives say have led to scarce supplies of treatments like…
Philips Suspends Sales of CPAP and Other Breathing Devices After Recall
Under a settlement with regulators, the company must revamp some operations before resuming sales of its CPAP and ventilator devices in the United States.
Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.
With Covid deaths rising to about 1,500 per week, researchers question why Paxlovid use has remained low among high-risk patients.